EichorEICHOR
Condition: Flt3 Mutated Acute Myeloid Leukemia Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Flt3 Mutated Acute Myeloid Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Hangzhou Polymed Biopharmaceuticals, Inc. · NCT07137637Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05024552Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07259707SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Phase 1/Phase 2 · 21 location(s) · Technische Universität Dresden · NCT04385290Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · 227 location(s) · National Cancer Institute (NCI) · NCT06317649MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07463651Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487Revumenib in Combination With 7+3 + Midostaurin in AML
Phase 1 · 2 location(s) · Richard Stone, MD · NCT06313437ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute My
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05010122A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patien
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT05886049Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in
Phase 2 · 20 location(s) · French Innovative Leukemia Organisation · NCT06022003A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Phase 1 · 1 location(s) · Shijiazhuang Yiling Pharmaceutical Co. Ltd · NCT07162116Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated
Phase 1 · 23 location(s) · Lomond Therapeutics Holdings, Inc. · NCT06366789
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.